^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carmustine

    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    7d
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Aug 2032 | Trial primary completion date: May 2030 --> Oct 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)
    8d
    Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • plerixafor
    13d
    hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)
    P2, N=16, Recruiting, Leland Metheny | Suspended --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH2 mutation
    |
    temozolomide • carmustine • Neupogen (filgrastim)
    22d
    The effect of combination therapy on Bevacizumab, Carmustine, and Metformin chemotherapy drugs on the fluctuating performance expression of TLR2, TLR6, and IL-6 genes in the cell line of brain glioblastoma. (PubMed, Cancer Cell Int)
    The combination of bevacizumab, carmustine, and metformin exerts a potent synergistic antitumor effect in U87MG glioblastoma cells through modulation of inflammation-associated genes, induction of apoptosis, and disruption of cell cycle progression. These findings provide a mechanistic rationale for multi-targeted combination therapy in glioblastoma and support further preclinical evaluation.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TLR2 (Toll Like Receptor 2)
    |
    Avastin (bevacizumab) • carmustine • metformin
    1m
    Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov)
    P2, N=150, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ALK positive
    |
    cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim)
    2ms
    A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=40, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • carmustine • melphalan
    2ms
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Not yet recruiting, Thomas Jefferson University | Trial completion date: Feb 2027 --> Mar 2032 | Trial primary completion date: Jan 2027 --> May 2030
    Trial completion date • Trial primary completion date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)
    2ms
    A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=47, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Oct 2025 | Trial primary completion date: Jul 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • carmustine • Istodax (romidepsin) • melphalan
    2ms
    Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment (clinicaltrials.gov)
    P2, N=45, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • cytarabine • etoposide IV • Inokai (orelabrutinib) • carmustine • melphalan
    3ms
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Not yet recruiting, Thomas Jefferson University | Initiation date: Apr 2025 --> Aug 2025
    Trial initiation date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)
    3ms
    SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov)
    P1, N=10, Recruiting, General Oncology, Inc. | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PALB2 mutation
    |
    BRACAnalysis CDx™
    |
    carmustine • melphalan • Mustargen (mechlorethamine)
    4ms
    hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)
    P2, N=16, Suspended, Leland Metheny | Recruiting --> Suspended
    Trial suspension
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH2 mutation
    |
    temozolomide • carmustine • Neupogen (filgrastim)